Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: Current concepts

Annals of Vascular Surgery

Volumn 25, Issue 6, 2011, Pages 846-855

  Joviliano, Edwaldo Edner ^a   Piccinato, Carlos Eli ^a   Dellalibera Joviliano, Renata ^a   Moriya, Takachi ^a   Évora, Paulo R B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MATRIX METALLOPROTEINASE 17; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; NITINOL; PACLITAXEL; RAPAMYCIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BARE METAL STENT; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CORONARY STENT; CYTOTOXICITY; DRUG ELUTING STENT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; IN-STENT RESTENOSIS; INFLAMMATION; INTERMITTENT CLAUDICATION; LEUKOCYTE ACTIVATION; MONOCYTE; MYOFIBROBLAST; NEOINTIMA; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SHEAR STRESS; SMOOTH MUSCLE FIBER; STENT; TISSUE REACTION; UNSTABLE ANGINA PECTORIS; VASCULITIS;

ANGIOPLASTY, BALLOON; BIOLOGICAL MARKERS; CYTOKINES; DRUG-ELUTING STENTS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MUSCLE, SMOOTH, VASCULAR; PEPTIDE HYDROLASES; PERIPHERAL ARTERIAL DISEASE; PROSTHESIS DESIGN; RECURRENCE; STENTS; TREATMENT OUTCOME;

EID: 80053452786     PISSN: 08905096     EISSN: 16155947     Source Type: Journal    
DOI: 10.1016/j.avsg.2011.02.026     Document Type: Review

References (124)

1. Heinrich J, Schulte H, Schoenfeld R, et al. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995;73:374-379.
2. Rasmussen TE, Hallett JW. New insights into inflammatory aortic aneurysms. Eur J Vasc Endovasc Surg 1997;14: 329-332. (Pubitemid 27511415)
3. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-428. (Pubitemid 28090212)
4. Liuzzo G, Biasucci L, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424. (Pubitemid 24247397)
5. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-1065. (Pubitemid 26125131)
6. Forrester JS, Fishbein M, Helfant R, et al. A paradigm for restenosis based on cell biological clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-769.
7. Serrano CV, Ramires JA, Venturinelli M, et al. Coronary angioplasty results in leucocyte and platelet activation with adhesion molecule expression: evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997;29:1276-1283. (Pubitemid 27201946)
8. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31: 224-230. (Pubitemid 28064746)
9. Yutani C, Ishibashi-Ueda H, Suzuki T, et al. Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis. Cardiology 1999;92:171-177. (Pubitemid 30162737)
10. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986;314:488-500.
11. Cwikiel W. Re-stenosis after balloon angioplasty and/or stent insertion-origin and prevention. Acta Radiol 2002;43:442-454.
12. Hoffman R, Mintz GS, Dussaillant RG, et al. Patterns and mechanisms of in stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-1254. (Pubitemid 26307249)
13. Moreno PR, Palacios IF, Leon MN, et al. Histopathologic comparison of human coronary in stent and post balloon angioplasty restenotic tissue.AmJ Cardiol 1999;84:462-466.
14. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999;10:499-506. (Pubitemid 30064019)
15. Lowe HC, Oesterle SN, Khachigan LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002;39:183-193. (Pubitemid 34084620)
16. Mehran R, Dangas G, Abizaid A, et al. Angiographics patterns of in stent restenosis: classification and implications for long-term outcome. Circulation 1999;100: 1872-1878. (Pubitemid 29511140)
17. O'Brian ER, Schwartz SM. Update of biology and clinical study of restenosis. Trends Cardiovasc Med 1994;4:169-178. (Pubitemid 24286927)
18. Ross R. Atherosclerosisd-an inflammatory disease. N Engl J Med 1999;340:115-126.
19. Orford JL, Selwyn AP, Ganz P, et al. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000;86(Suppl.):6H-11H.
20. Koch W, Tiroch K, Von Beckerath N, et al. Tumor necrosis factor-alpha, lymphotoxin-alpha and interleukin-10 gene polimorphisms and restenosis after coronary artery stenting. Cytokine 2003;24:161-171. (Pubitemid 37297879)
21. Blum A, Scheneider DJ, Sobel BE, Dauerman HL. Endothelial dysfunction and inflammatory after Percutaneous coronary intervention. Am J Cardiol 2004;94:1420-1423. (Pubitemid 39556215)
22. Li JJ, Fang CH, Jaing H, Huang CX. Increased C-reactive protein level after renal stent implantation in patients with atherosclerotic renal stenosis. Angiology 2004;55: 479-484.
23. Bennett MR. In-stent restenosis: pathology and implications for the development of drug eluting stent. Heart 2003;89:218-224. (Pubitemid 36115115)
24. Bosch JL, Hunink MG. Meta-analysis of the results of Percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology 1997;204: 87-96. (Pubitemid 27281713)
25. Tetteroo E, Van der Graaf Y, Bosch JL, et al. Dutch Iliac Stent Trial Study Group. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Lancet 1998;351: 1153-1159.
26. Adar R, Critchfield GC, Eddy DM. A confidence profile analysis of the results of femoropopliteal percutaneous transluminal angioplasty in the treatment of lowerextremity ischemia. J Vasc Surg 1989;10:57-67. (Pubitemid 19187559)
27. Schillinger M, Exner M, Mlekusch W, et al. Inflammatory response to stent implantation: differences in femoropopliteal, iliac, and carotid arteries. Radiology 2002;224: 529-535. (Pubitemid 34809137)
28. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-1880. (Pubitemid 28509283)
29. Li JJ, Li Z, Li J. Is inflammation a contributor for in-stent restenosis? Med Hypotheses 2007;68:945-951.
30. Schillinger M, Haumer M, Shlerka G, et al. Restenosis after percutaneous transluminal angioplasty in patients with peripheral artery disease: the role of inflammation. J Endovasc Ther 2001;8:477-483. (Pubitemid 33032462)
31. Landry DB, Couper LL, Bryant SR, et al. Activation of the NF11370B and I11370B system in smooth muscle cells after rat arterial injury: induction of VCAM-1 and MCP- 1. Am J Pathol 1997;151:1085-1095. (Pubitemid 27424318)
32. Yasukawa HI, Imaizumi T, Matsuoka H, et al. Inhibition of intimal hyperplasia after balloon injury by antibodies to ICAM-1 and LFA-1. Circulation 1997;95:1515-1522.
33. Cole EW, Hagen PO, Mikat E, et al. Association of polymorphonuclear leukocytes with sites of aortic catheterinduced injury in rabbits. Atherosclerosis 1987;67: 229-236.
34. Tanaka H, Sukhova G, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1997;88:1788-1803.
35. Verheyen AK, Vlaminckz EM, Lauwers FM, et al. Identification of macrophages in intimal thickening of rat carotid arteries by cytochemical localization of purine nucleotide phosphorylase. Arteriosclerosis 1988;8:759-767. (Pubitemid 19005361)
36. Wilcox JN, Okamoto EI, Nakahara KI, et al. Perivascular responses after angioplasty may contribute to postangioplasty restenosis: a role for circulating myofibroblasts precursor? Ann J Hum Genet 2000;947:187-195.
37. Amento EP, Ehsani N, Palmer H, et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991;11:1223-1230.
38. Suzuki H, Sunayama S, Kawal S, et al. ECM remodeling in restenotic human coronary atherosclerotic plaque of balloon angioplasty. J Am Coll Cardiol 1997;29:421A.
39. Bai H, Masuda J, Johanson K, et al. Neointima formation after vascular stent implantation: Spatial and chronological distribution of smooth muscle cell proliferation and phenotypic modulation. Arterioscler Thromb 1994;14:1846-1853.
40. Schuwartz RS, Huber KC, Murphy JG, et al. Re-stenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-274.
41. Grewe PH, Deneke T, Marchaoui A, et al. Acute and cronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35: 157-163. (Pubitemid 30061274)
42. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-466. (Pubitemid 27077826)
43. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-172.
44. Krepel VM, van Andel GJ, van Erp WF, et al. Percutaneous transluminal angioplasty of femoropopliteal artery: initial and long term results. Radiology 1985;156:325-328. (Pubitemid 15029756)
45. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty: factors influencing long term success. Circulation 1991;83:I70-I80.
46. Johnston KW. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology 1992;183: 767-771.
47. Buffon A, Liuzzo G, Biascucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-1521. (Pubitemid 29528666)
48. Cuneo AA, Autieri MV. Expression and function of antiinflammatory interleukins: the other side of the vascular response to injury. Curr Vasc Pharmacol 2009;1:715.
49. Libby P, Clintom SK. Cytokines as mediators of vascular pathology. Nouv Rev Fr Hematol 1992;34(Suppl.):S47-S53. (Pubitemid 23274737)
50. Libby P, Sukhova G, Lee RT, et al. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25(Suppl. 2):S9-S12. (Pubitemid 26084648)
51. Warner SJ, Libby P. Human vascular smooth cells: target for and source of tumor necrosis factor. J Immunol 1989;142:100-109. (Pubitemid 19034728)
52. Fukumoto Y, Shimokawa H, Ito A, et al. Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth- muscle phenotypes in pigs. J Cardiovasc Pharmacol 1997;29:222-231. (Pubitemid 27097725)
53. Clausell N, de Lima VC, Molossi S, et al. Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J 1995;73:534-539.
54. Libby P, Tanaka H. The molecular bases of restenosis. Prog Cardiovasc Dis 1997;40:97-106. (Pubitemid 27431107)
55. Couffinhal N, Duplaa C, Labat L, et al. Tumor necrosis factor -α stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler Thromb 1993;17: 490-497.
56. Jovigne S, Hultgardh-Nilsson A, Regnstrom J, et al. Tumor necrosis factor-α actives smooth muscle cell in culture and is expressed in the balloon-injured rat aorta. Arterioscler Thromb Vasc Biol 1997;17:490-497. (Pubitemid 27133138)
57. Tanaka H, Sukhova G, Schwartz D, et al. Proliferating arterial smooth muscle cells after balloon injury express TNF-α but not interleukin-1 or basic fibroblast growth factor. Arterioscler Thromb Vasc Biol 1996;16: 12-18. (Pubitemid 26026926)
58. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991;89:247-254.
59. Clausell N, Molossi S, Sett S, et al. In vivo blockade of tumor necrosis factor-α in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation 1994;89:2768-2779.
60. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147. (Pubitemid 26086851)
61. Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988;81: 487-498. (Pubitemid 18075245)
62. Wyble CW, Hynes KL, Kuchibhotla J, et al. TNF-alpha and IL-1 upregulate membrane-bound and soluble E-selection through a common pathway. J Surg Res 1997;73:107-112. (Pubitemid 28067293)
63. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells: molecular Trojan horses and cellular saboteurs. J Biol Chem 1997;272:22975- 22978. (Pubitemid 27392417)
64. Stopeck AT, Nicholson AC, Mancini FP, et al. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J Biol Chem 1993;268: 17489-17494. (Pubitemid 23236992)
65. Rectenwald JE, Moldawer LL, Huber TS, et al. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000;3:1697-1702.
66. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene-174G>C and -572G>C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001;2001(21):1457-1463.
67. Exner M, Schillinger M, Minar E, et al. Interleukin 6 genotype and restenosis after balloon angioplasty: initial observation. Radiology 2004;231:839-844. (Pubitemid 38668106)
68. Caixeta AM, Brito FS, Costa MA, et al. Enhanced inflammatory response to coronary stenting marks development of clinically relevant restenosis. Catheter Cardiovasc Interv 2007;69:500-507. (Pubitemid 46363850)
69. Li JJ, Fang CH, Jiang H, Huang CX. Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal artery stenosis. Clin Chim Acta 2004;350:115-121. (Pubitemid 39458253)
70. Gach O, Biemar C, Nys M, Deby-Dupont G, Cahpelle JP, Deby C, et al. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina. Coron Artery Dis 2005;16:59-65. (Pubitemid 40279600)
71. Jian-Jun LI. Inflammatory response, drug-eluting stent and restenosis. Chin Med J 2008;121:566-572.
72. Palmar JH, Aslam M, Standfield NJ. Percutaneous transluminal angiolplasty of lower limb arteries causes a systemic inflammatory response. Ann Vasc Surg 2009;23:569-576.
73. Versaci F, Gaspardone G. Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis 2004;15:307-311. (Pubitemid 39299244)
74. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses 2004;62:499-506.
75. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82: 515-518. (Pubitemid 28389953)
76. Cuneo AA, Autieri MV. Expression and function of antiinflammatory interleukins: the other side of the vascular response to injury. Curr Vasc Pharmacol 2009;7:267-276.
77. Mallat Z, Heymes C, Ohan J, et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999;19:611-616. (Pubitemid 29135162)
78. Fichtlscherer S, Breuer S, Heeschen C, et al. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 2004;44:44-49. (Pubitemid 38968454)
79. Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res 2001;49:882-890. (Pubitemid 32178392)
80. George J, Mulkins M, Shaish A, et al. Interleukin (IL)-4 deficiency does not influence fatty streak formation in C57BL/6 mice. Atherosclerosis 2000;153:403-411. (Pubitemid 32120340)
81. Grohmann U, Van Snick J, Campanile F, et al. IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10. J Immunol 2000;164:4197-4203. (Pubitemid 30215078)
82. Borkakoti N. Structural studies of matrix metalloproteinases. J Mol Med 2000;78:261-268. (Pubitemid 30489710)
83. Auble DT, Brinckerhoff CE. The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts. Biochemistry 1991;30:4629-4635.
84. Lijnen HR, Lupu F, Moons L, et al. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost 1999;81:799-807. (Pubitemid 29216569)
85. Murphy G, Knauper V, Atkinson S, et al. Cellular mechanisms for focal proteolysis and the regulation of the microenvironment. Fibrinolysis Proteolysis 2000;14:165-174. (Pubitemid 30409289)
86. Wu K, Setty S, Mauer SM, et al. Altered kidney matrix gene expression in early stages of experimental disease. Acta Anat 1997;158:155-165.
87. Schaefer L, Han X, Gretz N, et al. Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han: SPRD rat. Kidney Int 1996;49:75-81. (Pubitemid 26024229)
88. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circulation Res 1995;77:863-873.
89. Leco KJ, Khokha R, Pavloff N, et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix associated protein with a distinctive pattern of expression in mouse cells. J Biol Chem 1994;269:9352-9360. (Pubitemid 24209266)
90. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-122. (Pubitemid 27455388)
91. Rajagopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-2579. (Pubitemid 26415078)
92. Milkiewicz M, Kelland C, Colgan S, Haas TL. Nitric oxide and p38 MAP kinase mediate shear stress-dependent inhibition of MMP-2 production in microvascular endothelial cells. J Cell Physiol 2006;208:229-237. (Pubitemid 43849009)
93. Sinha I, Hannawa KK, Ailawadi G, et al. The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase- 9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. Ann Vasc Surg 2006;20:92-98. (Pubitemid 43029864)
94. Brown DL, Hibbs MS, Kearney M, Isner JM. Differential expression of 92-kDa gelatinase in primary atherosclerotic versus restenotic coronary lesions. Am J Cardiol 1997;79: 878-882. (Pubitemid 27197918)
95. Blankenberg S, Rupprecht HJ, Poirier O, et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107: 1579-1585.
96. Orbe J, Fernandez L, Rodrnguez JA, et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions: relation to plaque features and vascular bed. Atherosclerosis 2003;170:269-276. (Pubitemid 37377799)
97. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001;39:380-384. (Pubitemid 32529917)
98. Beaudeux JL, Giral P, Bruckert E, et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases- 1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003;169: 139-146. (Pubitemid 36830932)
99. Cedro K, Radomski A, Radomski MW, et al. Release of matrix metalloproteinase- 9 during balloon angioplasty in patients with stable angina: a preliminary study. Int J Cardiol 2003;92:177-180. (Pubitemid 37509979)
100. Southgate KM, Fisher M, Banning AP, et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res 1996;79:1177-1187. (Pubitemid 26404150)
101. Hojo Y, Ikeda U, Katsuki T, et al. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 2002;161:185-192. (Pubitemid 34214835)
102. Li C, Cantor WJ, Nili N, et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol 2002;39:1852-1858. (Pubitemid 34595299)
103. Cherr GS, Motew SJ, Travis JA, et al. Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates. Arterioscler Thromb Vasc Biol 2002;22:161-166. (Pubitemid 34076248)
104. Bendeck MP, Conte M, Zhang M, et al. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002;160: 1089-1095. (Pubitemid 34224595)
105. Muhs BE, Plitas G, Delgado Y, et al. Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1-matrix metalloproteinase following acute hindlimb ischemia. J Surg Res 2003;111:8-15. (Pubitemid 36808694)
106. Tayebjee MH, Tan KT, MacFadyen RJ, Lip GY. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Intern Med 2005;257:110-116. (Pubitemid 40129132)
107. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17: 463-516. (Pubitemid 33096184)
108. Williams TN, Zhang CX, Game BA, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through FcgRII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004;24: 61-66. (Pubitemid 38082412)
109. Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Invest Med 2003;51: 295-300. (Pubitemid 37210891)
110. Preston GA, Barrett CV, Alcorta DA, et al. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels. Nephron 2002;92:817-823. (Pubitemid 36151362)
111. Schofer J, Schluter M, Gershlick AH, et al. Sirolimuseluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries; double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362: 1093-1099. (Pubitemid 37222332)
112. Li JJ, Xu B, Yang YJ, et al. Drug-eluting stent for the treatment of small coronary lesions: comparison between sirolimus- and paclitaxel-eluting stent. Chin Med J 2007;120: 569-573. (Pubitemid 46629911)
113. Li JJ, Li J, Nan JL, et al. Coronary restenotic reduction of drug-eluting stenting may be due to its antiinflammatory effect. Med Hypotheses 2007;69:1004-1009. (Pubitemid 47430235)
114. Nuhrenberg TG, Voisard R, Fahlisch F, et al. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J 2005;19:246-248. (Pubitemid 40189270)
115. Scheinert D, Ulrich M, Scheinert S, et al. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. EuroIntervention 2006;2: 169-174.
116. Siablis D, Karnabatidis D, Katsanos K, et al. Sirolimuseluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther 2007;14:241-250. (Pubitemid 46776123)
117. Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical limb ischemia. J Endovasc Ther 2009;16(Suppl. II):II31-II62.
118. Duda SH, Pusich B, Richter G, et al. Sirolimus eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106: 1505-1509.
119. Duda SH, Bosiers M, Lammer J, et al. Drug eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006;13: 701-710. (Pubitemid 44907633)
120. Bosiers M, Cagiannos C, Deloose K, et al. Drug eluting stents in the management of peripheral arterial disease. Vasc Health Risk Manag 2008;4:553-559. (Pubitemid 352037915)
121. Dake M. Interim report on the Zilver PTX clinical trial. Paper presented at: International Symposium on Endovascular Therapy, January 28-February 1, 2007, Hollywood, FL.
122. Dake M. The Zilver PTX global registry and RCT (interview). Endovascular Today 2008;63-64.
123. Zeller T, Macharzina R, Tepe G. The potential role of DES in peripheral in-stent restenosis. Cardiovasc Surg (Torino) 2010;51:561-565.
124. Rathi S, Latif F, Exaire JE, Hennebry TA. Use of simultaneous angioplasty and in situ thrombolysis with a specialized balloon catheter for peripheral interventions. J Thromb Thrombolysis 2009;28:77-82.